{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:56:52Z","timestamp":1780325812088,"version":"3.54.1"},"reference-count":45,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Epstein\u2013Barr virus (EBV), a member of the Herpesviridae family, maintains a lifelong latent infection in human B cells. Switching from the latent to the lytic phase of its lifecycle allows the virus to replicate and spread. The viral lytic cycle is induced in infected cultured cells by drugs such as sodium butyrate and azacytidine. Lytic reactivation can be inhibited by natural products and pharmaceuticals. The anticonvulsant drugs valproic acid and valpromide inhibit EBV in Burkitt lymphoma cells. Therefore, other drugs that treat neurological and psychological disorders were investigated for effects on EBV lytic reactivation. Clozapine, an atypical antipsychotic drug used to treat schizophrenia and bipolar disorder, was found to inhibit the reactivation of the EBV lytic cycle. Levels of the viral lytic genes BZLF1, BRLF1, and BMLF1 were decreased by treatment with clozapine in induced Burkitt lymphoma cells. The effects on viral gene expression were dependent on the dose of clozapine, yet cells were viable at an inhibitory concentration of clozapine. One metabolite of clozapine\u2014desmethylclozapine\u2014also inhibited EBV lytic reactivation, while another metabolite\u2014clozapine-N-oxide\u2014had no effect. These drugs may be used to study cellular pathways that control the viral lytic switch in order to develop treatments for diseases caused by EBV.<\/jats:p>","DOI":"10.3390\/v11050450","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T11:06:46Z","timestamp":1558091206000},"page":"450","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Inhibition of Epstein-Barr Virus Lytic Reactivation by the Atypical Antipsychotic Drug Clozapine"],"prefix":"10.3390","volume":"11","author":[{"given":"Abbie G.","family":"Anderson","sequence":"first","affiliation":[{"name":"Department of Chemistry &amp; Biochemistry, University of Wisconsin-La Crosse, 1725 State St., La Crosse, WI 54601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cullen B.","family":"Gaffy","sequence":"additional","affiliation":[{"name":"Department of Chemistry &amp; Biochemistry, University of Wisconsin-La Crosse, 1725 State St., La Crosse, WI 54601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua R.","family":"Weseli","sequence":"additional","affiliation":[{"name":"Department of Chemistry &amp; Biochemistry, University of Wisconsin-La Crosse, 1725 State St., La Crosse, WI 54601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Gorres","sequence":"additional","affiliation":[{"name":"Department of Chemistry &amp; Biochemistry, University of Wisconsin-La Crosse, 1725 State St., La Crosse, WI 54601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0065-230X(06)97004-3","article-title":"Lytic Cycle Switches of Oncogenic Human Gammaherpesviruses1","volume":"97","author":"Miller","year":"2007","journal-title":"Adv. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0042-6822(79)90455-0","article-title":"Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate","volume":"94","author":"Luka","year":"1979","journal-title":"Virology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/ijc.2910280204","article-title":"Activation of the epstein-barr virus genome by 5-aza-cytidine in latently infected human lymphoid lines","volume":"28","author":"Klein","year":"1981","journal-title":"Int. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1128\/JVI.02659-10","article-title":"Valproic Acid Antagonizes the Capacity of Other Histone Deacetylase Inhibitors To Activate the Epstein-Barr Virus Lytic Cycle","volume":"85","author":"Tuck","year":"2011","journal-title":"J. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e00113","DOI":"10.1128\/mBio.00113-16","article-title":"Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus","volume":"7","author":"Gorres","year":"2016","journal-title":"MBio"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/cn400121z","article-title":"Classics in chemical neuroscience: Clozapine","volume":"4","author":"Wenthur","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s13311-017-0552-9","article-title":"Clozapine as a Model for Antipsychotic Development","volume":"14","author":"Nucifora","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/295160a0","article-title":"New Epstein\u2013Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma","volume":"295","author":"Heston","year":"1982","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1128\/jvi.61.12.3672-3679.1987","article-title":"Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency","volume":"61","author":"Countryman","year":"1987","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1128\/jvi.63.9.3878-3883.1989","article-title":"The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators","volume":"63","author":"Kenney","year":"1989","journal-title":"J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1128\/jvi.63.12.5276-5284.1989","article-title":"The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R","volume":"63","author":"Buisson","year":"1989","journal-title":"J. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"10694","DOI":"10.1128\/JVI.01172-09","article-title":"Stimulus Duration and Response Time Independently Influence the Kinetics of Lytic Cycle Reactivation of Epstein-Barr Virus","volume":"83","author":"Himmelfarb","year":"2009","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00004714-199404000-00006","article-title":"Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients","volume":"14","author":"Centorrino","year":"1994","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Subramanian, S., V\u00f6llm, B.A., and Huband, N. (2017). Clozapine dose for schizophrenia. Cochrane Database Syst. Rev., 2017.","DOI":"10.1002\/14651858.CD009555.pub2"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical Pharmacokinetics of Atypical Antipsychotics A Critical Review of the Relationship Between Plasma Concentrations and Clinical Response","volume":"46","author":"Mauri","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/0004867412438871","article-title":"A review of the use of clozapine levels to guide treatment and determine cause of death","volume":"46","author":"Stark","year":"2012","journal-title":"Aust. New Zeal. J. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1177\/0269881107077221","article-title":"Effects of haloperidol, clozapine and olanzapine on the survival of human neuronal and immune cells","volume":"21","author":"Heiser","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"ref_18","first-page":"999","article-title":"A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo","volume":"53","author":"Gardner","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0278-5846(98)00035-9","article-title":"Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients","volume":"22","author":"Chang","year":"1998","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4103\/0253-7613.77334","article-title":"Newer molecules in the treatment of schizophrenia: A clinical update","volume":"43","author":"Ghosh","year":"2011","journal-title":"Indian J. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejphar.2011.07.031","article-title":"The clozapine metabolite N-desmethylclozapine displays variable activity in diverse functional assays at human dopamine D 2 and serotonin 5-HT 1A receptors","volume":"669","author":"Heusler","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13674","DOI":"10.1073\/pnas.1835612100","article-title":"N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- D-aspartate receptor activity","volume":"100","author":"Sur","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0922-4106(93)90126-T","article-title":"Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists","volume":"245","author":"Hietala","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0014-2999(96)00671-1","article-title":"Effects of clozapine metabolites and chronic clozapine treatment on rat brain","volume":"314","author":"Kuoppamiiki","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3389\/fphar.2018.01049","article-title":"Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis","volume":"9","author":"Numata","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MOH.0000000000000391","article-title":"Clozapine-induced agranulocytosis\/granulocytopenia","volume":"25","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3109\/08923973.2013.828744","article-title":"Regulation of macrophage immune responses by antipsychotic drugs","volume":"35","author":"Chen","year":"2013","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.schres.2012.06.020","article-title":"Immunomodulatory effects of clozapine and their clinical implications: What have we learned so far?","volume":"140","author":"Andersen","year":"2012","journal-title":"Schizophr. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3109\/08923973.2011.651535","article-title":"Clozapine inhibits Th1 cell differentiation and causes the suppression of IFN-\u03b3 production in peripheral blood mononuclear cells","volume":"34","author":"Chen","year":"2012","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1017\/S1461145713001752","article-title":"Antipsychotic drug-associated gene\u2013miRNA interaction in T-lymphocytes","volume":"17","author":"Gardiner","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/656370","article-title":"Second-Generation Antipsychotics and Extrapyramidal Adverse Effects","volume":"2014","author":"Divac","year":"2014","journal-title":"Biomed Res. Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.pharmthera.2018.06.012","article-title":"Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences","volume":"192","author":"Aringhieri","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2003.09.010","article-title":"What\u2019s atypical about atypical antipsychotic drugs?","volume":"4","author":"Meltzer","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0079-6123(08)00910-2","article-title":"Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin\u2013dopamine hypothesis","volume":"172","author":"Kuroki","year":"2008","journal-title":"Prog. Brain Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/cimm.1995.1092","article-title":"Serotonin Upregulates Mitogen-Stimulated B Lymphocyte Proliferation through 5-HT1AReceptors","volume":"163","author":"Iken","year":"1995","journal-title":"Cell. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000292646","article-title":"Serotonin Receptor 3A Expression in Normal and Neoplastic B Cells","volume":"77","author":"Rinaldi","year":"2010","journal-title":"Pathobiology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1182\/blood.V99.7.2545","article-title":"5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: Reversal by selective serotonin reuptake inhibitors","volume":"99","author":"Serafeim","year":"2002","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8028","DOI":"10.1128\/JVI.00722-14","article-title":"Activation and Repression of Epstein-Barr Virus and Kaposi\u2019s Sarcoma-Associated Herpesvirus Lytic Cycles by Short- and Medium-Chain Fatty Acids","volume":"88","author":"Gorres","year":"2014","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1874467210902010095","article-title":"Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection","volume":"2","author":"Monti","year":"2010","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.1128\/AAC.01367-16","article-title":"N-Desmethylclozapine, Fluoxetine, and Salmeterol Inhibit Postentry Stages of the Dengue Virus Life Cycle","volume":"60","author":"Medigeshi","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0920-9964(97)00007-8","article-title":"Metabolites of the antipsychotic agent clozapine inhibit the replication of human immunodeficiency virus type 1","volume":"25","author":"Buthod","year":"1997","journal-title":"Schizophr. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/13550280390195342","article-title":"Early events in the life cycle of JC virus as potential therapeutic targets for the treatment of progressive multifocal leukoencephalopathy","volume":"9","author":"Baum","year":"2003","journal-title":"J. Neurovirol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Diem, O., Sch\u00e4ffner, M., Seifarth, W., and Leib-M\u00f6sch, C. (2012). Influence of Antipsychotic Drugs on Human Endogenous Retrovirus (HERV) Transcription in Brain Cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030054"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.virol.2016.09.012","article-title":"Mood stabilizers inhibit cytomegalovirus infection","volume":"499","author":"Ornaghi","year":"2016","journal-title":"Virology"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/5\/450\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:52:50Z","timestamp":1760187170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/5\/450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5]]}},"alternative-id":["v11050450"],"URL":"https:\/\/doi.org\/10.3390\/v11050450","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,17]]}}}